Methylene Blue in Severe Sepsis and Septic Shock

• Status: Unknown status
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to see whether the intravenous administration of methylene blue improves the outcome in severe sepsis and septic shock.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Methylene Blue

Criteria

Inclusion Criteria:

• Septic shock meeting the criteria of 2012 surviving sepsis campaign

• Need the norepinephrine of over 0.2microgram/kg/min

Exclusion Criteria:

• Pregnancy

• Less than 18 years old

• Terminal cancer patients

• Declined consents

• glucose-6-phosphate dehydrogenase deficiency

• Medication of Serotonin modulator